Welcome! We regret to inform you that the Injury Board National News Desk has been discontinued. Feel free to browse around and enjoy our previously published articles, or visit The Injury Blog Network for the latest in personal injury news.

FDA Alert: Avastin And Anemia

Posted by Jane Akre
Wednesday, July 16, 2008 11:16 AM EST
Category: Major Medical, Protecting Your Family
Tags: FDA and Prescription Drugs, Avastin, Dangerous Drugs, Breast Cancer, Colon Cancer, Drug Products

Avandia when combined in a drug trial has led to anemia, FDA reports.



IMAGE SOURCE: ©iStockPhoto/ Woman w. breast cancer bracelets/ author: JBryson


Genentech Inc has issued a warning about patients being treated with its cancer drug Avastin.

The San Francisco-based company reported to the FDA several cases of anemia in patients taking Avastin in a cancer drug trial.   

The Food and Drug Administration (FDA) has posted an alert on its Web site. Doctors prescribing the drug for colon, lung, and breast cancers are asked to report any cases of anemia to the FDA or Genentech.

Adverse reports can also be sent to the FDA online on the agency’s MedWatch Voluntary Reporting Form. 

Avastin is the company’s blockbuster cancer drug presently being combined with Pfizer Inc’s Sutent in a Phase 1 of a kidney cancer drug trial.

The microangiopathic hemolytic anemia observed in several patients involved in the trial, led to the closure of the trial of the two drugs, which are not approved or recommended to be combined, according to Genentech.

Microangiopathic hemolytic anemia results in a loss of red blood cells.

Two other trials were stopped mid-stage involving the two drugs because of fatigue, gastrointestinal complications and a suppression of blood cells and platelets.  Those trials involved patients with breast and lung cancer.

Avastin is approved to treat colon, lung and breast cancer. And with quarterly sales of $640, Avastin is expected to be Genentech’s most important drug.  The drug works by cutting of the supply of blood to tumors.

Sutent treats advanced kidney cancer.  

In the letter by Genentech posted on the FDA Web site, the company said that five of 12 patients who were treated with the highest dose of Sutent have been diagnosed with microangiopathic hemolytic anemia.  

Two of the most severe cases were reversed with three weeks of therapy and a discontinuation of the drugs.

Avastin will be combined with other therapies to be used in other trials.

Shares of Genentech fell 2 percent last week after reports questioned whether Avastin is worth its high price - generally costing an estimated $100,000 per patient a year.  #

No Comments

Comments for this article are closed.

About the National News Desk

Our mission is to seek the complete truth and provide a full and fair account of the events and issues that surround personal safety, accident prevention, and injury recovery.  We are committed to serving the public with honesty and integrity in these efforts.

Hurt in an accident? Contact an Injury Board member

Subscribe to Blog Updates

Enter your email address if you would like to receive email notifications when comments are made on this post.

Email address


RSS Feed

Add the National News Desk to your favorite RSS reader

Add to Google Reader Add to myYahoo Add to myMSN Add to Bloglines Add to Newsgator Add to Netvibes Add to Pageflakes